Concise Drug Review: Pazopanib and Axitinib

被引：71

作者：

van Geel, Robin M. J. M. ^{[1
]}

Beijnen, Jos H. ^{[2
,3
]}

Schellens, Jan H. M. ^{[1
,4
]}

机构：

[1] Netherlands Canc Inst, Div Clin Pharmacol, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands

[2] Slotervaart Hosp, Dept Pharm, Amsterdam, Netherlands

[3] Univ Utrecht, Div Biochem Anal, Div Drug Toxicol, Utrecht, Netherlands

[4] Univ Utrecht, Dept Pharmaceut Sci, Fac Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands

来源：

ONCOLOGIST | 2012年 / 17卷 / 08期

关键词：

Pazopanib; Axitinib; Drug profile; Angiogenesis; VEGF; ADVANCED SOLID TUMORS; RENAL-CELL CARCINOMA; MULTIKINASE ANGIOGENESIS INHIBITOR; PHASE-I TRIAL; OPEN-LABEL; CANCER; EFFICACY; PHARMACOKINETICS; AG-013736; COMBINATION;

D O I：

10.1634/theoncologist.2012-0055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pazopanib and axitinib are both U.S. Food and Drug Administration approved ATP-competitive inhibitors of the vascular endothelial growth factor receptor. Pazopanib and axitinib have been shown to be effective and tolerable treatment options for patients with metastatic renal cell cancer and therefore have enlarged the armamentarium for this disease. This concise drug review discusses the clinical benefits, clinical use, mechanism of action, bioanalysis, pharmacokinetics, pharmacogenetics, pharmacodynamics, drug resistance, toxicity, and patient instructions and recommendations for supportive care for these two drugs. The Oncologist 2012;17:1081-1089

引用

页码：1081 / 1089

页数：9

共 46 条

[1] Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-Small-Cell Lung Cancer [J].

Altorki, Nasser ;

Lane, Maureen E. ;

Bauer, Thomas ;

Lee, Paul C. ;

Guarino, Michael J. ;

Pass, Harvey ;

Felip, Enriqueta ;

Peylan-Ramu, Nili ;

Gurpide, Alfonso ;

Grannis, Frederic W. ;

Mitchell, John D. ;

Tachdjian, Sabrina ;

Swann, R. Suzanne ;

Huff, Anne ;

Roychowdhury, Debasish F. ;

Reeves, Anthony ;

Ottesen, Lone H. ;

Yankelevitz, David F. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3131-3137

[2]

[Anonymous], ONC DRUGS ADV COMM M

[3]

[Anonymous], 2012, INL AX TABL FULL PRE

[4]

[Anonymous], 2009, VOTR PAZ TABL FULL P

[5]

Australian Government Department of Health and Aging [Internet], AUSTR PUBL ASS REP P

[6]

Bender JLG, 2011, J CLIN ONCOL, V29

[7] Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status [J].

Bhargava, Pankaj ;

Robinson, Murray O. .

CURRENT ONCOLOGY REPORTS, 2011, 13 (02) :103-111

[8] Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study [J].

Bible, Keith C. ;

Suman, Vera J. ;

Molina, Julian R. ;

Smallridge, Robert C. ;

Maples, William J. ;

Menefee, Michael E. ;

Rubin, Joseph ;

Sideras, Kostandinos ;

Morris, John C., III ;

McIver, Bryan ;

Burton, Jill K. ;

Webster, Kevin P. ;

Bieber, Carolyn ;

Traynor, Anne M. ;

Flynn, Patrick J. ;

Goh, Boon Cher ;

Tang, Hui ;

Ivy, Susan Percy ;

Erlichman, Charles .

LANCET ONCOLOGY, 2010, 11 (10) :962-972

[9] Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics [J].

Brennan, Meghan ;

Williams, J. Andrew ;

Chen, Ying ;

Tortorici, Michael ;

Pithavala, Yazdi ;

Liu, Yingxue Cathy .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (05) :645-655

[10]

Bukowski Ronald M, 2011, Cancer Manag Res, V3, P273, DOI 10.2147/CMR.S15557

← 1 2 3 4 5 →